IL7 and hematologic disorder: Intriguingly, recent studies have reported that in certain tumor types (e.g., hematologic malignancies), exogenous recombinant IL-7 (such as long-acting IL-7) combined with chimeric antigen receptor T (CAR-T) cell therapy suppresses tumor progression by enhancing T cell function [49, 62].